Telix Pharmaceuticals (TLX) Stock Statistics & Valuation Metrics

Telix Pharmaceuticals has a market cap or net worth of $4.85B. The enterprise value is AU$8.56B.

Telix Pharmaceuticals has 338,721,340 shares outstanding. The number of shares has decreased by -2.65% in one year.

Telix Pharmaceuticals’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 6.06%.

The current PE Ratio of Telix Pharmaceuticals is 281.1. Telix Pharmaceuticals’s PEG ratio is 0.20.

In the last 12 months, Telix Pharmaceuticals had revenue of 783.21M and earned 49.92M in profits. Earnings per share was 0.15.

In the last 12 months, operating cash flow was 36.39M and capital expenditures -30.47M, giving a free cash flow of 5.92M billion.

Telix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Telix Pharmaceuticals upcoming earnings date is Feb 19, 2026, TBA (Confirmed).

Telix Pharmaceuticals as a current ratio of 2.78, with Debt / Equity ratio of 99.13%

In the past 12 months, Telix Pharmaceuticals has paid 6.14M in taxes.

Telix Pharmaceuticals EV to EBITDA ratio is 86.69, with an EV/FCF ratio of 891.69.

Telix Pharmaceuticals has $207.16M in cash and marketable securities with $418.25M in debt, giving a net cash position of -$211.10M billion.

Gross margin is 56.78%, with operating margin of 10.49%, and net profit margin of 6.37%.

The average price target for Telix Pharmaceuticals is $28.05, which is 11.43% higher than the current price. The consensus rating is Strong Buy